首页>
外国专利>
COMBINATION THERAPY WITH ANTI-CD74 AND ANTI-CD20 ANTIBODIES IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
COMBINATION THERAPY WITH ANTI-CD74 AND ANTI-CD20 ANTIBODIES IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
展开▼
机译:复发和难治性B细胞非霍奇金淋巴瘤患者的抗CD74和抗CD20抗体联合治疗
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention concerns methods of treating relapsed/resistant non-Hodgkin's lymphoma using combination therapy with an anti-CD20 antibody or fragment and an anti-CD74 antibody or fragment. In preferred embodiments, the antibody combination is administered along with at least one other therapeutic agent. The combination is effective to treat indolent NHL that is resistant to or relapsed from at least one therapy for NHL, including but not limited to rituximab resistant NHL. The antibody combination may be administered to human subjects at specific dosages and dosing schedules, that are effective to treat the disease but do not induce a dose-limiting toxicity.
展开▼